Caladrius Biosciences (NASDAQ:CLBS) is set to issue its quarterly earnings data before the market opens on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

Shares of Caladrius Biosciences (NASDAQ:CLBS) opened at $5.75 on Wednesday. The stock has a market cap of $52.56, a price-to-earnings ratio of 2.73 and a beta of 1.46. Caladrius Biosciences has a 12-month low of $2.63 and a 12-month high of $7.79.

CLBS has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Wednesday, November 15th. HC Wainwright set a $7.00 price target on shares of Caladrius Biosciences and gave the stock a “buy” rating in a research report on Friday, January 19th.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. grew its stake in Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,380 shares of the biotechnology company’s stock after purchasing an additional 4,163 shares during the period. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 as of its most recent SEC filing. 5.75% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.